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P arkinson’s disease (PD) is the second most com-mon neurodegenerative disease worldwide.  The 
characteristic pathology is the loss of dopamine (DA) 
neurons in the substantia nigra pars compacta (SNpc) 
and the appearance of α-synuclein (α-Syn)-containing 
cytoplasmic inclusion Lewy bodies in the surviving 
neurons.  When the number of nigral DA neurons is 
reduced by 30%,  motor symptoms such as akinesia/
bradykinesia,  tremor,  rigidity,  and postural instability 
appear [1].  In addition,  PD patients also exhibit 
non-motor symptoms such as constipation,  hyposmia,  
orthostatic hypotension,  depression,  anxiety,  halluci-
nations,  and sleep disorders,  which often precede 
motor symptoms [2].  Braak et al.  reported that Lewy 
pathology in the central nervous system (CNS) appears 
first in the brainstem and olfactory bulb,  and then 
spreads progressively through the SN and amygdala to 
reach the cerebral cortex [3].  Furthermore,  several 
studies have reported that PD pathology was detected 
early in the peripheral nervous system including 
Auerbach’s and Meissner’s plexuses in the gut [4 , 5].  
Therefore,  it is hypothesized that PD pathology propa-
gates from the enteric nervous system (ENS) to the 
CNS,  in part,  via the vagal nerve [6].  Indeed,  epide-
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Parkinson’s disease (PD) is the second most common neurodegenerative disease worldwide.  The loss of 
nigrostriatal dopaminergic neurons produces its characteristic motor symptoms,  but PD patients also have 
non-motor symptoms such as constipation and orthostatic hypotension.  The pathological hallmark of PD is the 
presence of α-synuclein-containing Lewy bodies and neurites in the brain.  However,  the PD pathology is 
observed in not only the central nervous system (CNS) but also in parts of the peripheral nervous system such as 
the enteric nervous system (ENS).  Since constipation is a typical prodromal non-motor symptom in PD,  often 
preceding motor symptoms by 10-20 years,  it has been hypothesized that PD pathology propagates from the 
ENS to the CNS via the vagal nerve.  Discovery of pharmacological and other methods to halt this progression 
of neurodegeneration in PD has the potential to improve millions of lives.  Astrocytes protect neurons in the 
CNS by secretion of neurotrophic and antioxidative factors.  Similarly,  astrocyte-like enteric glial cells (EGCs) 
are known to secrete neuroprotective factors in the ENS.  In this article,  we summarize the neuroprotective 
function of astrocytes and EGCs and discuss therapeutic strategies for the prevention of neurodegeneration in 
PD targeting neurotrophic and antioxidative molecules in glial cells.
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miological studies reported that vagotomy reduced the 
risk of PD [7].  Clearly,  it is desirable to find approaches 
that inhibit the progression of neurodegeneration in 
both the CNS and ENS.
Astrocytes are the most abundant glial cells in the 
CNS and play an important role in the maintenance of 
the neuronal environment: specifically,  regulation of 
extracellular ion concentration and energy supply [8].  
Astrocytes secrete neurotrophic and antioxidative fac-
tors and prevent neurodegeneration.  Indeed,  various 
studies have demonstrated the neuroprotective effects of 
astrocytes in models of neurodegenerative diseases.  We 
recently reported astrocyte-targeting dopaminergic 
neuroprotection in PD models [9 , 10].  In the ENS,  
astrocyte-like enteric glial cells (EGCs) play important 
roles in protecting enteric neurons by secretion of neu-
rotrophic and antioxidative factors [11-13].  In this 
review,  we summarize the neuroprotective functions of 
astrocytes and EGCs in the CNS and ENS,  respectively,  
especially focusing on neurotrophic and antioxidative 
molecules.
Astrocyte-Mediated Dopaminergic 
Neuroprotection in the CNS
Neuroprotection by neurotrophic factors secreted by 
astrocytes. Astrocytes secrete neurotrophic factors 
such as glial cell line-derived neurotrophic factor 
(GDNF),  brain-derived neurotrophic factor (BDNF),  
nerve growth factor (NGF),  mesencephalic astrocyte- 
derived neurotrophic factor (MANF),  and cerebral 
dopamine neurotrophic factor (CDNF) [9 , 14].  GDNF 
is a protein consisting of 134 amino acids that belongs to 
the transforming growth factor (TGF)-β superfamily 
[15 , 16].  It is found in cultured cells derived from mes-
encephalic neurons and is a potent dopaminergic neu-
roprotective factor [17].  GDNF is expressed mainly in 
neurons in the normal condition; conversely,  astro-
cytes express and secrete the protein in diseased brains 
[11].  It was reported that GDNF overexpression increased 
the number of dopaminergic neurons in the SNpc and 
dopaminergic nerve terminals in the striatum of mice 
[18].  Intracerebroventricular injection of GDNF 
up-regulated DA content in neurotoxin 6-hydroxydo-
pamine (6-OHDA)-treated PD model rats [19].  In 
addition,  GDNF restored DA levels in the midbrain 
and ventral tegmental area and improved motor symp-
toms in rhesus monkeys of PD model induced by injec-
tion of 1-methyl-4-phenyl-1 , 2 , 3 , 6-tetrahydropyridine 
(MPTP) [20].  Thus,  GDNF could be a potent neuro-
protectant in PD.  However,  GDNF cannot pass through 
the blood-brain barrier (BBB); therefore,  research on 
GDNF delivery using viral vectors is underway.  
Lentiviral vector-based delivery of GDNF showed neu-
roprotection against 6-OHDA-induced neurotoxicity 
[21].  In addition,  it is reported that several DA D1 and 
D2 agonists up-regulate the expression of GDNF in 
astrocytes [22 , 23].
MANF and CDNF are the known neurotrophic fac-
tors secreted by astrocytes [24 , 25].  Under normal con-
ditions these proteins are primarily localized in the 
endoplasmic reticulum (ER) and are secreted in 
response to ER stress [26].  MANF and CDNF reduce 
ER stress and exert pro-survival effects on neurons.  It 
has been reported that overexpression or chronic treat-
ment with CDNF or MANF prevents dopaminergic 
neurodegeneration in 6-OHDA-injected PD models 
[27-29].  As a potential therapeutic target,  CDNF has 
the advantage of a wide distribution in the brain [30].
Neuroprotection by antioxidative molecules pro-
duced by astrocytes. Astrocytes are also known to 
produce antioxidative molecules such as glutathione 
(GSH) and metallothionein (MT)-1 , 2 [31 , 32].  GSH is 
a well-known intrinsic antioxidant against reactive oxy-
gen species.  Previous studies reported that GSH levels 
were decreased in the SN of PD patients [33 , 34].  
Therefore,  up-regulation of GSH could be a neuropro-
tective treatment for PD.  GSH is a tripeptide composed 
of glutamate,  cysteine,  and glycine.  Neurons need to 
take up cysteine for GSH synthesis.  However,  extracel-
lular cysteine is readily oxidized to the oxidized 
homodimer cystine [35],  and neurons lack the cystine/
glutamate exchange transporter (xCT),  the main pro-
tein for bringing cystine into cells [36 , 37].  Astrocytes 
do express xCT for cystine uptake,  and reduce it to 
cysteine for the synthesis of GSH [38].  Astrocytes 
release the synthesized GSH into the extracellular space 
via multidrug resistance-associated protein 1 (MRP1) 
[39 , 40].  The extracellular GSH is then reduced by 
disulfide-exchanging or peptidase reactions to produce 
cysteine,  which is taken up by neighboring neurons and 
used for GSH synthesis in neurons [9].  Thus,  GSH syn-
thesis in neurons is dependent on cystine uptake by 
astrocytes and their synthesis and release of GSH 
[9 , 41].  We previously reported that the antiepileptic 
drugs,  zonisamide and levetiracetam,  upregulated xCT 
expression followed by GSH synthesis in astrocytes and 
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protected dopaminergic neurons in parkinsonian mod-
els [42 , 43].  It is also reported that stimulation of D2 
receptors on astrocytes promotes GSH synthesis via 
activation of nuclear factor erythroid 2-related factor 2 
(Nrf2) and protects neurons against MPTP-induced 
dopaminergic neurotoxicity in vitro and in vivo [44].  
Nrf2 is a master transcription factor to produce various 
phase II-detoxifying enzymes and antioxidative mole-
cules including GSH and MT-1 , 2 [45 , 46].
Metallothioneins bind to heavy metals such as cop-
per,  cadmium,  and zinc,  and function in metal 
homeostasis and detoxification [47 , 48].  MTs contain 
20-cysteine residues and exert antioxidative properties 
[49].  There are four isoforms,  MT-1,  -2,  -3 and -4;  
MT-1 , 2 are expressed in most organs including the 
brain,  and the proteins are mainly produced by astro-
cytes [50].  MT-1 , 2 expression is increased in astrocytes 
in the SN of PD patients [51].  Our previous studies 
demonstrated that astrocytes produced MT-1 , 2 in 
response to oxidative stress,  and extracellular MT-1 , 2 
prevented dopaminergic neurotoxicity [45].  Further-
more,  we previously reported that stimulation of sero-
tonin (5-HT) 1A receptors on astrocytes promoted 
astrocyte proliferation and expression/secretion of 
MT-1 , 2 in/from astrocytes [52].  Taken together,  
upregulation of MT-1 , 2 and 5-HT1A stimulation in 
astrocytes could be a target of neuroprotection in PD.
Novel Neuroprotective Agents Targeting 
Astrocytic 5-HT1A Receptors
Rotigotine,  a DA agonist,  is used to treat PD.  
Rotigotine binds to DA D1-D5 receptors,  with a partic-
ularly high affinity for D2,  D1 and D3 receptors,  in that 
order [53].  In addition,  rotigotine possesses 5-HT1A 
partial agonistic properties [54].  Our recent study 
demonstrated dopaminergic neuroprotective effects of 
rotigotine via 5-HT1A receptors in PD models [55].  
Rotigotine treatment promoted astrocyte proliferation 
and MT-1 , 2 expression in astrocytes.  The rotigotine- 
induced upregulation of MT-1 , 2 in astrocytes was 
mediated by Nrf2 activation.  Pretreatment with condi-
tioned medium from rotigotine-treated astrocytes 
inhibited 6-OHDA-induced dopaminergic neurotoxic-
ity via astrocytic 5-HT1A receptors and secretion of 
MT-1 , 2.  Furthermore,  daily subcutaneous adminis-
tration of rotigotine increased MT-1 , 2 expression in 
astrocytes and prevented the reduction of dopaminergic 
neurons in the SNpc of 6-OHDA-injected PD model 
mice.  These effects were blocked by co-administration 
with a 5-HT1A receptor antagonist.  These results sug-
gest that rotigotine exerts neuroprotective effects by 
upregulation of MT-1 , 2 expression in astrocytes via 
5-HT1A receptors.
Mirtazapine is a noradrenergic and specific seroto-
nergic antidepressant (NaSSA).  It increases extracellu-
lar levels of noradrenaline and 5-HT by blocking pre-
synaptic α2 adrenergic receptors on noradrenergic and 
serotonergic nerve terminals.  In addition,  mirtazapine 
inhibits 5-HT2 and 5-HT3 receptors to indirectly stim-
ulate 5-HT1A receptors.  We have demonstrated the 
neuroprotective effects of mirtazapine by upregulation 
of MT-1 , 2 expression in astrocytes via 5-HT1A recep-
tors [56].  A previous study demonstrated that 5-HT1A 
receptor agonists improved motor dysfunction and 
L-dopa-induced dyskinesia in PD model animals [57].  
Mirtazapine also improves motor- and non-motor 
symptoms in PD patients [58 , 59].  These results suggest 
that mirtazapine could be a possible disease-modifying 
agent for PD [56].
As mentioned above,  rotigotine also upregulated 
antioxidative molecules in astrocytes and ameliorated 
dopaminergic neurodegeneration via 5-HT1A receptors 
[55].  Taken together with these experimental results,  
targeting the 5-HT1A receptor on astrocytes may be a 
possible strategy for neuroprotection in PD [9].
Role of Glial Cells in the ENS
EGCs are counterparts of astrocytes in the CNS.  
EGCs express GFAP and represent the morphological 
features of astrocytes [60].  The astrocytic glial cells that 
support neurons and nerve fibers in the ENS were first 
described by Dogiel in 1899 [61].  EGCs are classified 
into 1-4 subtypes based on their morphology and dis-
tribution [60].  EGCs interact with neurons and epithe-
lial cells by secreting neurotrophic factors and bioactive 
molecules [62].  Calcium imaging studies demonstrated 
EGC activation in response to neuronal activity in the 
ENS [63].  These Ca2+-mediated interactions between 
EGCs and neurons can modulate intestinal motility 
[64].  Furthermore,  it is reported that EGCs are acti-
vated in response to the release of neurotransmitters 
such as acetylcholine (ACh) and 5-HT [65-67].  
Collectively,  these reports suggest that the interaction 
between EGCs and enteric neurons may regulate intes-
tinal motility.  It is also reported that EGCs are involved 
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in maintaining the mucosal lining and repairing barrier 
function by secreting several mediators [62 , 68].  A 
study of EGC-knockdown mice showed that their intes-
tinal cell permeability was increased,  although intesti-
nal motility was significantly decreased [69].  These 
results indicate that EGCs work to maintain intestinal 
permeability.  EGCs are activated by inflammation and 
secrete GDNF to improve the barrier function of the 
intestine [70].  In addition,  EGCs express major histo-
compatibility complex II (MHCII),  respond to noxious 
inputs via toll-like receptors (TLR)-2 and -4,  and regu-
late immune function in the ENS via the release of 
pro-inflammatory cytokines [71].  Furthermore,  EGCs 
themselves function as antigen-presenting cells for both 
innate and acquired immune systems [72].  Thus,  EGCs 
have an important role in intestinal motility,  mucosal 
lining,  and immune responses in the ENS.  As men-
tioned above,  accumulation of α-Syn has been observed 
in the ENS of PD patients with gastrointestinal disor-
ders such as constipation.  Moreover,  the proportion of 
EGCs expressing GFAP was increased in the ENS [73].  
EGCs could be involved in the pathogenesis of neuro-
degenerative diseases,  but their role is rather complex.
Enteric Neuroprotection Mediated by  
EGCs in PD Models
EGC-mediated enteric neuroprotection in the rote-
none-injected PD model. The ENS-neuroprotective 
roles of EGCs have been studied from several angles.  
Abdo et al.  demonstrated that the neuroprotective 
effects of EGCs against oxidative stress occur via the 
release of reduced GSH [74].  In addition,  the pesticide 
rotenone causes loss of the enteric plexus and decreased 
gastrointestinal motility [75]; thus,  we examined 
changes in MT-1 , 2 expression in the colonic myenteric 
plexus of rotenone-injected PD model mice [76].  
Subcutaneous administration of rotenone (50 mg/kg/
day) for 6 weeks increased MT expression and activated 
glial cells not only in the striatum but also in the colonic 
myenteric plexus.  Furthermore,  rotenone-induced 
neuronal loss of the myenteric plexus was aggravated in 
MT-1 , 2 knockout mice compared to wild-type mice,  
suggesting the neuroprotective effects of MT expression 
in the EGCs [76].  In addition,  upregulation of antioxi-
dative molecules,  such as GSH and MT,  in EGCs can 
provide neuroprotection in the ENS in PD.  Our previ-
ous study demonstrated that administration with caffeic 
acid (CFA) or chlorogenic acid (CGA),  polyphenol 
components of coffee,  inhibited the reduction in 
MT-1 , 2 expression in EGCs and prevented the loss of 
enteric plexus in low-dose rotenone-treated PD mice 
[77].  Several studies have reported that CFA and CGA 
activate the Kelch-like ECH-associated protein 1 
(Keap1)-Nrf2 pathway [78 , 79].  Therefore,  activation of 
the Nrf2 signaling pathway could be a target of neuro-
protection in the ENS.  Finally,  CDNF is also important 
as a neuroprotectant in the ENS.  CDNF knockout mice 
exhibited loss of intestinal Meissner’s plexus,  but not of 
nigral dopaminergic neurons [80].
Further investigation of the effects of rotenone found 
that it activates GFAP-positive glial cells in the ENS to 
cause impairment of intestinal motility [81].  In addi-
tion,  in the rotenone model using C. elegans,  dysfunc-
tion of mitochondrial complex I activated the innate 
immune response pathway via the p38 MAPK/ATF-7 
pathway and prevented dopaminergic denervation in 
the intestine [82].  Neuroprotection by p38 MAPK/
ATF-7 requires the autophagy mechanism and PINK-1,  
suggesting that p38 MAPK-mediated immunity acti-
vates mitophagy and results in neuroprotection.  These 
reports suggest that EGCs are activated by inflamma-
tory responses in the intestine and may be involved in 
the protection of enteric neurons and regulation of 
intestinal motility in the intestine.
Involvement of gut microbiota in the protection of 
enteric plexus. Recent studies have reported interac-
tions between gut microbiota and neurodegenerative 
diseases such as multiple sclerosis,  Alzheimer’s disease,  
and PD [83].  The mammalian gut microbiota is com-
posed of bacteria,  viruses,  yeasts,  and bacteriophages 
[84].  The gut microbiota plays important roles in food 
digestion,  vitamin synthesis,  angiogenesis,  epithelial 
cell maturation and development,  education of the host 
immune system,  and protection against pathogens.  The 
gut microbiota synthesizes neurotransmitters such as 
ACh,  γ-aminobutyric acid (GABA),  and 5-HT,  which 
can directly and indirectly affect physiological function 
in the CNS [85-87].  In addition,  short-chain fatty acids 
(SCFAs) produced by the gut microbiota in the presence 
of indigestible fiber maintain intestinal homeostasis by 
promoting the intestinal lining and mucus production 
as a barrier,  and promoting a pro-inflammatory per-
missive response; they also migrate to the CNS to 
restore the integrity of the BBB [88].  In PD patients,  
the composition of SCFAs was changed due to a 
decrease in butyrate acidophilic bacteria [89].  
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Transplantation of microbiota from PD patients into 
α-Syn-overexpressing mice enhanced motor disability 
compared with transplantation of microbiota from 
healthy human donors [90].  These findings suggest that 
gut bacteria can influence motor function in mice and 
that alterations in the human microbiome could be a 
risk factor for PD.  Recently,  it was reported that the 
addition of restraint stress (RS) to rotenone treatment 
enhanced rotenone-induced oxidative stress and 
increased expression of α-Syn,  GFAP,  and IL-1β in the 
intestine,  as well as dopaminergic neuronal loss and 
microglial activation in SN [91].  In this experiment,  
changes in the gut microbiota were also examined; RS 
decreased Lactobacillus populations and RS-plus-
rotenone treatment increased Akkermansia popula-
tions.  RS with or without rotenone also showed a 
decreasing trend of butyric acid content in feces,  which 
correlated with the data of PD patients.  These reports 
clarified the relationship between PD and intestinal 
inflammation,  or PD and EGC activation.  However,  
the direct connection between intestinal inflammation 
and EGC activation in PD is still obscure.
Conclusion
Astrocytes in the CNS and EGCs in the ENS provide 
neuroprotection by secretion of neurotrophic and anti-
oxidative molecules (Fig. 1).  Therefore,  up-regulation 
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Fig. 1　 Neuroprotection by glial cells in the CNS and ENS.  Astrocytes in the CNS and EGCs in the ENS provide neuroprotection by 
secretion of neurotrophic and antioxidative molecules.
of these molecules in astrocytes or glial cells could be a 
possible target of neuroprotection.  Since enteric mani-
festations of PD often precede motor dysfunction by 
10-20 years,  a neuroprotective approach in the ENS 
could be a potent therapeutic strategy to inhibit the ini-
tial enteric pathogenesis and progression of PD.
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